Stay updated with breaking news from Medication Guide. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Rates of non-fatal overdose events following SUBLOCADE treatment was lower compared to daily opioid agonist therapy.Data published in the Journal of Addition MedicineRICHMOND, Va., Sept. 26, 2023...
Subcutaneous EPKINLY™ is the first and only bispecific antibody approved in Japan to treat adult patients with certain types of relapsed/refractory large B-cell lymphoma after two or more lines...
Media Release Subcutaneous EPKINLYTM is the first and only bispecific antibody approved in Japan to treat adult patients with certain types of relapsed/refractory large B-cell lymphoma after two...
Company AnnouncementTEPKINLY® (epcoritamab) is the first and only subcutaneous bispecific antibody approved as a monotherapy for adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapyConditional marketing authorization approval from the Eur...
TEPKINLY® is the first and only subcutaneous bispecific antibody approved as a monotherapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of...